markdown

Connecticut’s Novel Approach to Tackle Drug Expenses

Connecticut has recently enacted a law aimed at curbing spending on weight-loss drugs for its state insurance program, HUSKY Health, which involves Medicaid and CHIP enrolments.

Limiting Costs and Exploring Alternatives

States have grappled with rising costs of drugs like Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound. These four drugs are projected to cost Connecticut around $140 million in the fiscal year 2024. In response, while some states have restricted the prescription of these drugs, Connecticut has expanded coverage.

A Strategic Petition

The recently signed bill directs the Commissioner of Social Services to petition the US Health and Human Services Department, led by Robert F. Kennedy Jr., to utilise the federal government’s right to own the patents of GLP-1s. The idea is to contract with generic manufacturers to produce versions of the drugs. “The commissioner may enter into a consortium with other states,” says the law.

Intellectual Property and Patent Concerns

A Legal Precedent

The law employs eminent domain principles found in section 28 US 1498 of the US Patent Code. If RFK Jr. approves the request, drugmakers could be compensated based on production costs rather than market rates. Robin Feldman, a law professor at the University of California, notes that recent cases have involved royalties of around 10% or 7.5%.

Historical and Ongoing Efforts

This approach hasn’t been attempted lightly. Similar strategies have been employed before, such as Louisiana’s attempts in 2017 and post-9/11 anthrax countermeasures. Louisiana eventually struck a deal to cap costs.

New Market Dynamics

There’s an interesting twist here: as prices begin to ease due to increased supply, companies seek to undercut the compounding market. This has led to vials being sold at cheaper prices via direct-to-consumer models. Former Novo Nordisk CEO Lars Jørgensen remarked on this phenomenon, noting the compounding market’s size.

Potential and Challenges

Connecticut considered using compounders but wasn’t comfortable without FDA approval. There’s also talk of importing from Canada as generic competition is on the horizon there, making this an intriguing alternative.

Voices of Caution and Opportunity

The Industry Response

Eli Lilly and others are monitoring developments, indicating concern for patent integrity. Meanwhile, advocates and experts are closely watching RFK Jr.’s possible responses. On the other hand, the Trump administration had shown limited success in managing these costs, as mentioned by Yale’s Amy Kapczynski.

Negotiation or Real Potential?

Some see this as a negotiation tactic more than a definite plan, given the government’s reluctance to undermine patents. Yet, Feldman asserts there could be a mutually beneficial outcome for drug companies and society.

Conclusion

Connecticut’s bold move, if successful, might set a precedent for other states. While the path is fraught with challenges and potential legal wrangles, it underlines a proactive stance towards healthcare affordability.

For more insights into health industry developments, follow Anjalee Khemlani and delve into in-depth analyses.